Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.

Name: Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.
Author: Kawamoto, Yasuyuki

Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603. — المؤلف: Kawamoto, Yasuyuki — The oncologist 20220809

المؤلف: Kawamoto, Yasuyuki
النشر: The oncologist 20220809
الوصف: e642-e649 p.
الموضوعات: Antibodies, Monoclonal, Humanized؛ Antineoplastic Combined Chemotherapy Protocols؛ Humans؛ Irinotecan؛ Stomach Neoplasms؛ Tumor Microenvironment؛ Vascular Endothelial Growth Factor A؛ Ramucirumab